MedTrace Logo

Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances

NCT02614027 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 276

Last updated 2018-07-02

No results posted yet for this study

Summary

To evaluate the prevalence of lipodystrophy syndrome in patients receiving currently available antiretroviral drugs, and the prevalence of associated metabolic syndrome in HIV-infected patients with a previous diagnosis of lipodystrophy syndrome, according to the severity of fat accumulation and antiretroviral drug use.

Conditions

  • Lipodystrophy
  • Metabolic Syndrome

Interventions

OTHER

Evaluation of metabolic syndrome

Evaluation and analytical determinations of the different components of the syndrome

OTHER

Evaluation of changes in fat by DXA while on current therapy

Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation

Sponsors & Collaborators

  • Asociacion para el Estudio de las Enfermedades Infecciosas

    lead NETWORK

Principal Investigators

  • Jose L Casado, MD · Ramon y Cajal Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-02-28
Completion
2018-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02614027 on ClinicalTrials.gov